Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: What do we really know?

Clinical Breast Cancer

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Chung, Cathie T ^a   Carlson, Robert W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Aminoglutethimide; Anastrozole; Endocrine therapy; Exemestane; Letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADRENAL SUPPRESSION; ARTHRALGIA; ARTHRITIS; ARTICLE; BONE DENSITY; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; DRUG FATALITY; DYSLIPIDEMIA; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HOT FLUSH; HUMAN; ITALY; LIPID METABOLISM; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

EID: 4644281244     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.s.010     Document Type: Article

References (17)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351:1451-1467.
2. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:684-690.
3. Stewart HJ, Prescott RJ, Forrest AP Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93:456-462.
4. Carlson RW, Anderson BO, Bensinger W, et al. The National Comprehensive Cancer Network breast cancer clinical practice guidelines in oncology. J Natl Compr Cancer Network 2003; 1:148-188.
5. Chung CT, Carlson RW. The role of aromatase inhibitors in early breast cancer. Curr Treat Options Oncol 2003; 4:133-140.
6. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
7. Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003; 26(4 suppl 1):S27-S33.
8. Boccardo F, Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001; 19:4209-4215.
9. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; 82(suppl 1):3 (Abstract #3).
10. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
11. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
12. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388.
13. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817-824.
14. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802-1810.
15. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with inegestrol acetate. J Clin Oncol 1998; 16:453-461.
16. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83:1142-1152.
17. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399-1411.